Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986259 in stabilized patients hospitalized for acute decompensated heart failure
MOH_2021-02-22_009669Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) and Acute Heart Failure (AHF) comparing BMS-986259 with Placebo (2 arms). Primary endpoint: Hypotension events. Started Jan 2021; status: completed.
02
Drugs
FA relaxin
03
Conditions
heart failure (HF)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on MOH_2021-02-22_009669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-22_009669.